| 1. |
UN initiatives for HIV/AIDS treatment programmes |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Anastrozole of global value in early breast cancer? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 3-4
L Hunt,
Preview
|
|
摘要:
In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, tamoxifen is associated with a number of adverse events that can limit its use. Adjuvant treatment with anastrozole [Arimidex] in postmenopausal women with early-stage breast cancer in the ATAC*trial was associated with superior efficacy, compared with tamoxifen, in terms of disease-free survival, time to recurrence, and the incidence of contralateral breast cancer. Furthermore, anastrozole has numerous noteworthy advantages in terms of tolerability compared with tamoxifen.1Several recent presentations at the 6th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting [Barcelona, Spain; November 2003] and the 26th Annual San Antonio Breast Cancer Symposium [Texas, US; December 2003] presented the results of pharmacoeconomic and outcome analyses of the ATAC study from the perspective of a number of countries.2,3,4,5,6Overall, the studies suggest that anastrozole is a cost-effective alternative to tamoxifen for the treatment of hormone-receptor positive (HR+) breast cancer tumours, and is within acceptable limits for reimbursement. This cost effectiveness is consistent across several countries with different healthcare systems.
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Infliximab cost-effectiveness study methods debated |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Management of hypertension, CVD risk recommendations released |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
A significant proportion of children recently diagnosed with autism receive complementary and alternative medicines |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
HAART introduction in Italy provides cost, QOL advantage |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Determining the cost of stress incontinence not to be sneezed at |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Postcode prescribing of antidementia drugs persists in the UK |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Alternative therapies commonly used among frail US elderly |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 13-13
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Budesonide/formoterol breathes QOL back into COPD patients |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 445,
2004,
Page 14-14
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
